In the present study, we observed an increased expression of MAP2, an important cytoskeleton‐associated protein expressed in dendrite and perikarya of the neuron.26, 27 It is similar to the reports in AD patients 28 and in old mice with cognitive decline.29 However, it is different from some studies in DE, VD, and AD, which showed decreased MAP2 in the brain.30, 31 Some previous studies suggested that the reduction of MAP2 was coincident with neuron loss in the brain, so the decrease in MAP2 might result from the reduction of the number of neurons directly. The gene discussed is MAP2; the disease is Alzheimer disease.